A national survey suggests up to 488,000 Australians may live with alopecia areata, with many self-diagnosing and going untreated despite significant psychological distress.
Hundreds of thousands of Australians may be living with alopecia areata, with many failing to seek medical care or treatment, according to a new survey that researchers say exposes a major gap in awareness and diagnosis.
The cross-sectional study of 8256 Australians found the lifetime prevalence of AA among people aged 15 years and older ranged from 1.2% to 2.3%, translating to an estimated 260,000 to 488,000 Australians affected by the autoimmune hair-loss condition.
Point prevalence estimates suggested between 192,000 and 294,000 Australians were currently experiencing active hair loss.
The full results have been published this month in the Australasian Journal of Dermatology.
The researchers said the findings substantially exceeded previous Australian estimates derived from electronic health records, which reported a point prevalence of just 0.13%, indicating many cases may never be formally diagnosed or captured in healthcare systems.
The study, conducted between August and September 2024, used the validated Alopecia Areata Assessment Tool in a quota-balanced online survey designed to reflect Australian Bureau of Statistics census distributions for age, sex and jurisdiction.
Among 194 participants identified with potential AA, 36% were self-diagnosed rather than diagnosed by a healthcare provider.
The researchers found self-diagnosed participants were more likely to report active hair loss than those with an established healthcare diagnosis, suggesting ongoing disease activity may not always translate into medical consultation or formal recognition.
The study also highlighted substantial treatment gaps. Nearly one-third of participants with healthcare provider-diagnosed AA reported using no treatment or management approach, while almost one-quarter of untreated participants said they were unaware of available treatment options.
Among those with diagnosed AA, topical prescription medicines were the most commonly used treatment, followed by over-the-counter topical products and shampoos or conditioners marketed for hair loss.
Injectable prescription medicines were used by fewer than 10% of participants.
“The most common reasons for nontreatment in HCP-diagnosed participants were minimal hair loss and natural hair regrowth,” the researchers wrote.
“This suggests that the study sample primarily captured individuals with mild disease.
“A higher proportion of participants with self-diagnosed AA reported current scalp hair loss than HCP-diagnosed participants, which may reflect current disease activity and care-seeking/diagnosis patterns (e.g., those currently flaring are less likely to have an established diagnosis).
“A high proportion of participants with potential AA had self-diagnosed AA (36.2%), underscoring the need for investment in AA education and increased screening efforts.”
Related
The psychological burden of the disease was also prominent. More than 70% of participants with diagnosed AA reported feeling anxious when first diagnosed, while almost 90% of self-diagnosed participants reported anxiety when they first experienced hair loss.
Depression was also common, with many participants continuing to report ongoing emotional distress.
The researchers said the findings reinforced the need for greater education among both clinicians and patients to improve recognition of AA, support earlier diagnosis and increase awareness of emerging therapies.
They also noted older Australians appeared particularly likely to remain untreated, despite persistent disease burden.
The researchers noted that the study relied on self-reported questionnaire data without physician confirmation, meaning some misclassification may have occurred.
However, they said the results provided the clearest picture to date of AA prevalence in Australia and suggest the condition was substantially under-recognised in routine clinical practice.
“The high prevalence of self-diagnosed AA and the high rate of untreated AA among HCP-diagnosed participants highlight the need for improved education to increase awareness about AA and its treatments among patients and HCPs in Australia,” the researchers concluded.
“Improved disease education could lead to earlier diagnosis of AA, increased access to available and emerging treatments, and better outcomes for patients.”
